期刊文献+

多形性胶质瘤母细胞瘤患者血清中miR-155、miR-365和BDNF的表达及意义 被引量:3

下载PDF
导出
摘要 目的探讨多形性胶质瘤母细胞瘤(glioblastoma multiforme,GBM)患者血清中miR-155、miR-365和脑源性神经营养因子(brain derived neurophic factor,BDNF)的表达及其相关性。方法运用荧光素报告载体系统检测miR-155和miR-365直接调控的靶基因BDNF。并收集54例GBM患者和12例Ⅰ、Ⅱ级胶质瘤患者的术前外周血标本,以20例健康志愿者的外周血标本作为对照,应用实时荧光定量PCR和酶联免疫吸附试验技术分别检测GBM和Ⅰ、Ⅱ级胶质瘤患者血清中miR-155、miR-365和BDNF的表达水平,分析miR-155、miR-365与BDNF的相关性。结果 BDNF是miR-155和miR-365直接调控的靶基因,miR-155或miR-365均可下调BDNF蛋白的表达;GBM患者血清中miR-155与miR-365的表达水平分别为6.59±1.22、6.96±1.43,两者分别与健康志愿者(1.19±0.24、1.07±0.16)比较,差异均有统计学意义(P<0.01);Ⅰ、Ⅱ级胶质瘤患者血清中miR-155与miR-365的表达水平分别为1.35±0.41、1.29±0.39,两者分别与健康志愿者比较,差异均无统计学意义(P>0.05)。GBM患者血清中的BDNF表达水平为(5.52±1.23)ng/mL,与健康志愿者[(12.55±2.11)ng/mL]比较,差异有统计学意义(P<0.01);Ⅰ、Ⅱ级胶质瘤患者BDNF表达水平为(11.83±3.43)ng/mL,与健康志愿者比较,差异无统计学意义(P>0.05)。相关性分析发现,miR-155与miR-365的表达呈正相关(rs=0.875,P<0.01),miR-155、miR-365的表达均与BDNF呈负相关(rs=-0.819,rs=-0.774,P<0.01)。结论 miR-155、miR-365和BDNF三者表达与GBM的发生发展密切相关,其有可能成为判断GBM疗效及预后的潜在生物学指标。
出处 《广东医学》 CAS CSCD 北大核心 2012年第15期2310-2312,共3页 Guangdong Medical Journal
  • 相关文献

参考文献2

二级参考文献22

  • 1Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38:225-262.
  • 2Thomas CM, Sweep CG. Serum tumor markers: past, state of the art, and future, lnt J Biol Markers 2001; 16:73-86.
  • 3Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J lntern Med 2007; 18:175-184.
  • 4Roulston JE. Limitations of tumour markers in screening. Br J Surg 1990; 77:961-962.
  • 5Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
  • 6Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
  • 7Chen C, Ridzon DA, Broomer A J, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
  • 8Tang F, Hajkova P, Barton SC, Lao K, Surani MA. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34:e9.
  • 9Hafner M, Landgraf P, Ludwig J, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008; 44:3-12.
  • 10Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-2261.

共引文献1006

同被引文献44

  • 1各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33024
  • 2Mimezami AH, Pickard K, Zhang L, et al. MicroRNAs: key players in carcinogenesis and novel therapeutic targets [J]. Eur J Surg Oncol, 2009, 35:339-347.
  • 3Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer[J]. World J Surg, 2009, 33:638-646.
  • 4Aukerman MJ, Sakai H. Regulation of flowering time and floral organ identity by a MicroRNA and its APETALA2-1ike target genes [J]. Plant Cell, 2003, 15(11): 2730-2741.
  • 5Sen GL, Blau HM. Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies [J]. Nat Cell Biol, 2005, 7 (6): 633-636.
  • 6Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology,and paths to treatment [J]. Genes Dev, 2007, 21(21): 2683-2710.
  • 7Stummer W Pichlmeier U, Meinei T, et al. Fluorescence-guided surge- ry with5-am-inolevulinic acid for resection of malignant glioma:a randomised controlled multicentre phase III trail [J]. Lancet Oncol, 2006, 7(5): 359-360.
  • 8Sabbah P, Foehrenbaeh H, Dutertre G, et al. Multimodal anatomic, functional,and metabolic brain imaging for tumor resection [J]. Clin Imaging, 2002, 26(1): 6-12.
  • 9D A Reardon, A Desjardins, J J Vredenburgh, et al. Metronomic chemotherapy with daily,oral etoposide plus bevacizumab for recurre- nt malignant glioma: a phase II study [J]. Br J Cancer, 2009, 101 (12): 1986-1994.
  • 10Imperato JP, Paleologos NA, Vick NA, et al. Effects of treatment on long-term survivors with malignant astrocytomas [J]. Ann Neurol, 1996, 28(6): 818-822.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部